1-7 of 7
Manuel Ayala, MD
Close
Sort by
Journal Articles

Nilotinib As Second or Third-Line Therapy for Myeloid Chronic Leukemia Chronic-Phase in Mexican Patients

Manuel Ayala, MD, Jacqueline Domínguez, NL, Antonieta Chavez, PhD
Journal: Blood
Blood (2016) 128 (22): 5459.
https://doi.org/10.1182/blood.V128.22.5459.5459
Published: 2016
Journal Articles

The Role of Peg-Interferon (P-IFN) in Salvaging Patients with Chronic Myeloid Leukemia Chronic Phase (LMC-CP) in Molecular Resistant (MolRes) to Second- Generation Tyrosine Kinase Inhibitors (TKIs)

Manuel Ayala, MD, Antonieta Chavez, PhD, Jacqueline Domínguez, NL
Journal: Blood
Blood (2016) 128 (22): 5461.
https://doi.org/10.1182/blood.V128.22.5461.5461
Published: 2016
Journal Articles

Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia

Manuel Ayala, MD, Jacqueline Domínguez, NL, Iván Bonilla, MD
Journal: Blood
Blood (2016) 128 (22): 5430.
https://doi.org/10.1182/blood.V128.22.5430.5430
Published: 2016
Journal Articles

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Jorge E. Cortes, MD, Carmino Antonio De Souza, PhD, Jose Luis Lopez, MD, Manuel Ayala, MD, Eduardo Bullorsky, Xiaojun Huang, Sandip Shah, K. Govind Babu, Tomasz Sacha, MD, Israel Bendit, Zhizhou Liang, Tina Owugah, Prasanna Kumar Nidamarthy, Tomasz Szczudlo, Carmen Piccolo, MD, Philipp D. le Coutre, MD
Journal: Blood
Blood (2013) 122 (21): 95.
https://doi.org/10.1182/blood.V122.21.95.95
Published: 2013
Journal Articles

Molecular Status Evaluation in a Standardized Laboratory in a Cohort of Patients with Chronic Myeloid Leukemia At the Instituto Mexicano Del Seguro Social (IMSS)

Luis A Meillón, MD, Carolina Sandoval-Sanchez, PhD, Nancy Delgado-Lopez, MD, Manuel Ayala, MD, Yolanda Lugo, Maria Mora, MD, Noe Diaz-Robles, MD, Patricia Oropeza, MD, Angelica Romo, MD, Kevin Nacho-Vargas, MD
Journal: Blood
Blood (2012) 120 (21): 4452.
https://doi.org/10.1182/blood.V120.21.4452.4452
Published: 2012
Journal Articles

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Manuel Ayala, MD, Rafael Hurtado Monroy, MD, Luis Meillon, MD, Nancy Delgado, MD, Elena Garcia, MD, Jorge Vela-Ojeda, MD, Pablo Vargas, MD, Norma Tapia, MD, Martha Alvarado, MD, Jose de Diego, MD, Patricio Azaola, MD, Roberto Hernandez, MD, Gustavo Reyes, MD, Martín de Jesús Gonzalez, MD, Alvaro Aguayo, Juan Julio Kassack, MD, Sergio Cleto, MD, Olga Cantu, MD, Kevin Nacho, MD, Angel Herrera, Ingrid Mucius
Journal: Blood
Blood (2008) 112 (11): 4275.
https://doi.org/10.1182/blood.V112.11.4275.4275
Published: 2008
Journal Articles

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Manuel Ayala, MD, Rafael Hurtado, MD, Kevin Nacho, MD, Norma Tapia, MD, Martha Alvarado, MD, Alvaro Aguayo, MD, Sergio Cleto, MD, Yolanda Lugo, MD, Gustavo Reyes, MD, Pablo Vargas, MD, Angel Herrera, Luis Antonio Meillon, MD
Journal: Blood
Blood (2007) 110 (11): 4578.
https://doi.org/10.1182/blood.V110.11.4578.4578
Published: 2007